[Skip to Content]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
[Skip to Content Landing]
Other Articles
December 1, 1951


Author Affiliations

667 Madison Ave., New York 21.

2 E. 95th St., New York 28.

JAMA. 1951;147(14):1381. doi:10.1001/jama.1951.03670310071029

This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.


To the Editor:  —There is no specific governmental regulation concerning the sterility of eye medicaments. Neither of the official compendia regulating the practice of pharmacy mentions the subject. As a result, even large pharmaceutical companies, supplying widely used and valuable drugs, dispensed on prescription in their original containers, are not required to adhere to any official standard procedure to insure sterility. If an individual retail pharmacist prepares a contaminated solution, since the drug is generally used by the patient immediately after preparation, the concentration of organisms is low and may not cause infection. Even if an infection does occur, the incident, while unfortunate, is limited to the one patient and generally is traced quickly to its source. However, when a large manufacturer releases an infected batch of a compound, which may number thousands of units, the situation may become disastrous before the shipment is recalled. During the long time interval

First Page Preview View Large
First page PDF preview
First page PDF preview